Research ended
Apogee Therapeutics, Inc. (APGE) was acquired by AbbVie for $135.11 a share in cash on 3 September 2026.
Our research on Apogee Therapeutics, Inc. ended on . Once a takeover closes, the shares stop trading under APGE and there is nothing left to research. The last note, from , is below.
We keep this page so links to it still work and what we published about the stock stays on the record.
The last thesis
Apogee Therapeutics has no tradable equity: AbbVie completed the $135.11-per-share cash purchase on 3 September 2026. AbbVie's 30 October 2026 report showed no change to the price, and the only open item is a Delaware appraisal window ending near 1 January 2027.